BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230711
DTEND;VALUE=DATE:20230714
DTSTAMP:20260516T064227
CREATED:20230302T092937Z
LAST-MODIFIED:20230302T092937Z
UID:36706-1689033600-1689292799@www.pharmajournalist.com
SUMMARY:2nd Digital Biomarkers & Clinical Measures in Neurology Summit
DESCRIPTION:CNS biopharma is rapidly investing in digital technologies to revolutionize clinical identification and monitoring of complex neurological disorders through more objective\, frequent\, sensitive\, and less invasive measures of movement\, speech\, and cognition. \nReturning to Boston\, the 2nd Digital Biomarkers & Clinical Measures in Neurology Summit is the only industry-specific meeting dedicated to developing translatable\, scalable\, and successful digital technologies and measures specifically to be incorporated into neurological clinical trials. \nThis is your must-attend meeting tackling the development of digital measures to revolutionize clinical assessments across neurological drug development. \nUniting Digital Health Biopharma with CNS Clinical Drug Developers to: \n\nAddress the Standardization & Regulatory Acceptance of Digital Tools & Data Analysis as Endpoints in Complex Neurological Indications\nDiscover Novel Innovations for Objective\, Sensitive\, & Non-Invasive Neurological Measures\nEnsure Confidence & Scalability with Emerging Digital Technologies\n\nTo know more visit: https://ter.li/nx0m2f
URL:https://www.pharmajournalist.com/event/2nd-digital-biomarkers-clinical-measures-in-neurology-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230711
DTEND;VALUE=DATE:20230714
DTSTAMP:20260516T064227
CREATED:20230405T231354Z
LAST-MODIFIED:20230405T231354Z
UID:37027-1689033600-1689292799@www.pharmajournalist.com
SUMMARY:2nd Annual Optimizing AAV Safety Summit 2023
DESCRIPTION:With more than 300 trials in preclinical and clinical development actively using AAV as their vector of choice\, the priority for any company working in this space is to ensure that each and every one of those therapies is the safest version it can be. \nIn this context\, the 2nd Annual Optimizing AAV Safety Summit is returning in 2023\, bringing together genetic therapy leaders across non-clinical development\, clinical development\, toxicology\, biodistribution\, and immunology who are all working to optimize the safety of their AAV-based drug products in their day-to-day. \nBy addressing key topics including how to extract the most relevant data from preclinical studies to better inform how humans will respond to an AAV-based therapy in the clinic\, analyzing potential integration risks of AAV serotypes\, and investigating regulatory approaches to safety packages for submission\, this meeting will inform how to streamline AAV safety processes to de-risk delays and shorten timelines to approval. \nJoin us in Boston to be part of the solution to bringing safer\, effective genetic therapies to patients and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development. \nTo know more visit: https://ter.li/6gzgy4
URL:https://www.pharmajournalist.com/event/2nd-annual-optimizing-aav-safety-summit-2023/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230712
DTEND;VALUE=DATE:20230714
DTSTAMP:20260516T064227
CREATED:20230404T110544Z
LAST-MODIFIED:20230404T110544Z
UID:37012-1689120000-1689292799@www.pharmajournalist.com
SUMMARY:Advanced Wound Care Summit US 2023
DESCRIPTION:The Advanced Wound Care Summit is wound care’s only industry-led forum \nIt’s a chance for senior executives to address shared challenges around innovative product development\, build meaningful partnerships\, and sharpen their R&D and commercial strategies. \nWhether an established wound care company\, an emerging startup\, an SME\, a regulator\, a payer\, or key opinion leader\, this event serves your strategic and commercial goals. \nTo take this chance to uncover how leading figures are leveraging novel clinical trial designs\, addressing reimbursement challenges surrounding skin substitute products\, progressing next generation diagnostic innovations\, and much more. \nTo know more visit: https://hubs.ly/Q01J-t480
URL:https://www.pharmajournalist.com/event/advanced-wound-care-summit-us-2023/
LOCATION:Boston\, Massachusetts
ORGANIZER;CN="Kisaco Research":MAILTO:Jodie.purser@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230718
DTEND;VALUE=DATE:20230721
DTSTAMP:20260516T064227
CREATED:20230414T110135Z
LAST-MODIFIED:20230414T110135Z
UID:37065-1689638400-1689897599@www.pharmajournalist.com
SUMMARY:3rd Tumor Myeloid-Directed Therapies Summit
DESCRIPTION:The 3rd Annual Tumor Myeloid-Directed Therapies Summit returns with over 75% new speakers to share insights across a range of myeloid targets\, including CD40\, CD39\, LILRB2\, CLEC-1 as well as CAR-M therapies. The one-stop shop continues to be your go-to forum to accelerate myeloid therapy progression by determining optimal combination strategy\, optimize translational studies\, discover novel targets\, and guarantee patient safety. Connect with this up-and-coming community to reinvent targeting and harness the untapped potential of the myeloid. \nCollaborate and learn from myeloid experts across industry and academia over 3 in-depth days of content\, as they address the key bottlenecks limiting the efficacy and safety of these exciting treatments\, including in vivo models\, biomarkers of response\, combination rationale\, and myeloid biology to accelerate myeloid directed therapies. \nTo know more visit: https://ter.li/tm1bzy
URL:https://www.pharmajournalist.com/event/3rd-tumor-myeloid-directed-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260516T064227
CREATED:20230405T225751Z
LAST-MODIFIED:20230405T225751Z
UID:37019-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:ADC Toxicity Summit
DESCRIPTION:There is a vast number of ADCs that never make it to the clinic let alone to market\, and this is largely due to toxicological challenges providing a narrow therapeutic index. Understanding the causes of toxicity\, their translatability into the clinic\, as well as mitigation and dosing strategies to limit these toxicities will enable ADC developers to take more assets into the clinic while reducing the costs of failures. \nThe inaugural ADC Toxicity Summit is coming to Boston\, MA this July 25-27 as the first and only meeting dedicated to enabling drug developers to analyze mechanisms of action\, discuss shared challenges associated with translating in vivo toxicity data to the clinic\, and optimizing dosing to minimize the toxicity of your drug and improve tolerability to bring more ADCs with a wider therapeutic index to market. \nTake a look at our 3-day event guide for your in-depth roadmap to the ADC Toxicity Summit. \nUniting all key stakeholders invested in this conversation ranging from toxicologist and pathologists\, through to nonclinical\, translational\, and clinical experts\, this is your exclusive opportunity to harness never before gained insights to deliver a safer and more tolerable generation of ADCs to patients. \n3 reasons why you can’t miss out on joining include: \n\nSelect optimal preclinical models for determining ADC toxicity profiles to enable improved translatability and ultimately improve clinical trial outcomes with Seagen and AbbVie\nHear how companies with commercially approved ADCs mitigated toxicities in the clinic\, and optimized their dosage allowing expansion of their therapeutic windows with ImmunoGen and the Dana Farber Cancer Institute\nUncover ideal linker stability and drug-antibody ratios to design an ADC with a lower toxicity profile with Bristol Myers Squibb\, Iksuda and Merck & Co\n\nHarnessing case-study led presentations and interactive discussions to enable you to select optimal models for your GLP toxicity studies\, mitigate ADC related toxicities in the clinic and optimize linker-design for more controlled payload release\, this is your exclusive opportunity to harness new insights to minimize the toxicity of your drug.
URL:https://www.pharmajournalist.com/event/adc-toxicity-summit/
LOCATION:Hyatt Regency Boston Downtown\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260516T064227
CREATED:20230516T104255Z
LAST-MODIFIED:20230516T104255Z
UID:37192-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:2nd Annual Targeted Radiopharmaceuticals Summit
DESCRIPTION:With the exciting news that Novartis has received US FDA approval for Pluvicto for previously-treated patients with PSMA-positive metastatic castration-resistant prostate cancer\, the TRP space is continuing to go from strength to strength. \nThis is why the upcoming 2nd Annual Targeted Radiopharmaceuticals Summit US program is even more comprehensive than ever\, bringing you a tracked agenda covering the whole TRP landscape from discovery\, translation\, to clinical\, late stage progress and challenges – a unique opportunity for your entire team to learn and network. \nJoin us to: \n\nExplore the novel target selection to re-route targeted radiopharmaceuticals from a niche-label therapeutic\nNavigate the regulation and reimbursement challenges to improve the accessibility of targeted radiopharmaceuticals\nReview theragnostic in the clinic to exploit the two-birds-one-stone potential of TRPs\nDiscover the potential combination therapies with DDRi’s and IO to unlock synergy with other modalities\nHarness the platform technologies for optimized preclinical evaluation of drugs\n\nAll presented by top industry players such as Clarity Pharmaceuticals\, SOFIE Biosciences\, Lantheus\, Fusion Pharmaceuticals\, Rayze Bio\, Telix Pharmaceuticals\, OranoMed\, Actinium Pharmaceuticals\, and many more. \nDownload the brand-new event guide here to see a full overview 3-day content and speaker faculty: https://ter.li/8hn0z2
URL:https://www.pharmajournalist.com/event/2nd-annual-targeted-radiopharmaceuticals-summit/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260516T064227
CREATED:20230601T114828Z
LAST-MODIFIED:20230601T114828Z
UID:37256-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:Fusion Protein Engineering & Developability Summit
DESCRIPTION:Design & Engineer Functional & Manufacturable Novel Fusion Proteins \nPrepare to be captivated by the Fusion Protein Engineering & Developability Summit\, the ultimate event tailored to drug developers with groundbreaking fusion protein pipelines. This conference is an absolute game-changer that should be at the top of your priority list! \nAs the demand for practical and effective engineering techniques to expedite the development of viable drugs into clinical applications skyrockets\, this highly anticipated summit offers an unrivalled opportunity. Join forces with esteemed experts from industry giants like Roche\, Merck\, Bristol Myers Squibb\, Abbvie\, and an array of other distinguished names. Seize this unique occasion to connect with fellow drug developers\, exchange innovative ideas and strategies\, and gain invaluable insights into cutting-edge fusion applications. \nPrepare for a whirlwind of activity across the action-packed three-day agenda\, including: \n\nCutting-Edge Insights: Gain exclusive access to the latest breakthroughs in fusion protein engineering\, encompassing the most recent research and emerging trends in this dynamic field.\nPractical Learning: Immerse yourself in hands-on workshops led by industry experts\, designed to enhance your skills and knowledge in must-know areas.\nReal-World Case Studies: Immerse yourself in over 17+ data-driven case studies presented by renowned drug developers\, offering profound insights and best practices.\nEngaging Discussions: Engage in lively panel discussions and roundtable sessions\, fostering debates and knowledge exchange on hot topics such as novel linker selection and the identification of PK/PD rules.\nNetworking Opportunities: Forge valuable connections with 60+ protein engineers\, therapeutic developers\, and influential industry leaders during 7+ hours of dedicated networking\, including the renowned speed networking session.\n\nWith a stellar lineup of 25+ speakers\, 3 immersive hands-on workshops\, and 2 days packed with data-driven case studies\, this event is set to become the unequivocal highlight of the year and you cannot afford to miss it! \nTo know more visit: https://ter.li/uuyrdu
URL:https://www.pharmajournalist.com/event/fusion-protein-engineering-developability-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260516T064227
CREATED:20230608T113503Z
LAST-MODIFIED:20230608T113503Z
UID:37317-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:4th Gamma Delta T Therapies Summit
DESCRIPTION:Established industry leaders and emerging innovators such as Adicet Bio\, IN8Bio\, Sanofi\, Merck\, LAVA Therapeutics\, Takeda and Leucid Bio are driving the race to demonstrate the potential of Gamma Delta T Therapies as cytotoxic\, off-the-shelf solid tumor therapies\, spurred by early indications of clinical efficacy. \nThe 4th Gamma Delta T Therapies Summit returns to Boston this July as the ultimate Industry-focused forum to advance your Gamma Delta T research\, spanning dedicated 2 tracks of content to maximize your Clinical & Product Optimization and Research & Translational Development. Join 150+ expert industry peers for 2 full days of sessions and a pre-conference workshop and deep-dive day\, building on early clinical successes\, highlighting process and engineering innovations and leveraging early clinical insights to cast the spotlight onto Gamma Delta T Therapies in the clinic. \nTo know more visit: https://ter.li/69o2yc
URL:https://www.pharmajournalist.com/event/4th-gamma-delta-t-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade Group":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230726
DTEND;VALUE=DATE:20230729
DTSTAMP:20260516T064227
CREATED:20230310T085409Z
LAST-MODIFIED:20230310T085611Z
UID:36783-1690329600-1690588799@www.pharmajournalist.com
SUMMARY:3rd mRNA-Based Therapeutics Summit
DESCRIPTION:The 3rd mRNA-Based Therapeutics Summit returns to Boston this July\, cementing its position as the world’s only end-to-end meeting focused on the next generation of mRNA-based therapeutics and vaccines. \nDownload the event program here. \nThis year’s meeting promises 75+ deep-dive case studies from a speaker faculty that is 85% new for this year’s agenda\, featuring presentations from the FDA\, Pfizer\, Moderna\, BioNTech\, Sanofi and many more. \n \nExpect 100+ world-class speakers from large pharma\, innovative biotechs\, and key opinion leaders of academia\, 5 dedicated tracks and 3 days of immersive content on discovery\, translation\, clinical development\, chemistry\, manufacturing and controls (CMC) and logistics to overcome industry hurdles of optimized dosing\, targeted delivery\, safety and scalability to achieve regulatory success in infectious and rare diseases\, cancer and beyond! \nRegister your team here to join 500+ mRNA experts in July.
URL:https://www.pharmajournalist.com/event/3rd-mrna-based-therapeutics-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR